Long-term efficacy and safety of dupilumab in patients enrolled from Latin American centers from the open-label extension LIBERTY ASTHMA TRAVERSE study.

Authors

Abraham Alí Munive, Marco Antonio Fernández Corzo, Adrián Rendón, Daniela Cavalet Blanco, Martti A Antila, Patricia Fernández, Ana Stok, Jérôme Msihid, Christine Cazeau, Rebecca Gall, Harry J Sacks, Juby A Jacob-Nara, Jorge F Máspero

Published in

The Journal of asthma : official journal of the Association for the Care of Asthma. Pages 1-16. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

Uncontrolled asthma is common among Latin American patients. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13, drivers of type 2 inflammation.
This post hoc analysis of 48-96 week open-label extension TRAVERSE (NCT0213402) study assessed dupilumab 300 mg every 2 weeks up to 148 weeks (parent study plus extension) in patients with moderate-to-severe asthma enrolled from Latin American centers who previously completed a dupilumab asthma study (phase 2b or phase 3 QUEST). Endpoints included treatment-emergent adverse events, severe asthma exacerbations, pre-bronchodilator forced expiratory volume in 1 second (FEV₁), 5-Item Asthma Control Questionnaire (ACQ-5), Asthma Quality of Life Questionnaire (AQLQ), and type 2 biomarkers.
A total of 596 (28.9%) patients were enrolled from Latin American centers. Safety was consistent with the known dupilumab safety profile. Annualized rate of severe exacerbations remained low across patients (0.115-0.459). Improvements in pre-bronchodilator FEV₁ were sustained to Week 96 (mean change from parent study baseline of 0.28-0.35 L) and in ACQ-5 and AQLQ scores to Week 48 (last assessed time-point). Patients receiving placebo during parent studies demonstrated improvements once switched to dupilumab in TRAVERSE. Patients receiving dupilumab during parent studies demonstrated further improvements in exacerbations, ACQ-5, and AQLQ. Type 2 biomarkers decreased over time.
Consistent with results in the overall population, long-term efficacy and safety of dupilumab was observed in patients with moderate-to-severe asthma with a treatment duration of up to 148 weeks, supporting the long-term benefits of dupilumab use in Latin American patients.

PMID:
42412510
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.